心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Neth Heart J.：STEMI患者旋动脉明显收缩预示危险信号

2015-05-05 范伟译 MedSci原创

STEMI旋动脉收缩
关注

背景：闭塞的旋动脉(Cx)通常在心电图中不会出现信号。在ST段抬高心肌梗死(STEMI)中，它会导致延迟的血管造影。这个分析的目的是右冠状动脉(RCA)狭窄的STEMI患者，左降动脉(LAD)用经皮冠状动脉介入治疗(PCI)后，确定闭塞的旋动脉收缩与其相比是否会有多样化的结果。方法和结果：入选标准如下：首先STEMI患者的左降动脉(LAD)用经皮冠状动脉介入治疗(PCI)，额外明显的(≥70%)闭

背景：闭塞的旋动脉(Cx)通常在心电图中不会出现信号。在ST段抬高心肌梗死(STEMI)中，它会导致延迟的血管造影。这个分析的目的是右冠状动脉(RCA)狭窄的STEMI患者，左降动脉(LAD)用经皮冠状动脉介入治疗(PCI)后，确定闭塞的旋动脉收缩与其相比是否会有多样化的结果。

方法和结果：入选标准如下：首先STEMI患者的左降动脉(LAD)用经皮冠状动脉介入治疗(PCI)，额外明显的(≥70%)闭塞的旋动脉或右冠状动脉RCA 收缩-两个-血管疾病。共有234名连续的STEMI患者包括在内。总死亡率在长期随访中评估，STEMI后平均639(±224)天。闭塞的旋动脉收缩的患者占研究人数的46%(N = 108)，右冠状动脉RCA收缩的患者达54%(N = 126)。闭塞的旋动脉收缩的患者相比于右冠状动脉RCA收缩的患者就死亡率而言长期结果更差(分别为22 vs 11%，p < 0.05)。多元回归分析显示长期随访中死亡的独立危险因素例如：年龄、射血分数和闭塞的旋动脉收缩。

如图：RCA组与Cx组的比较

结论：明显闭塞的旋动脉收缩相比右冠状动脉(RCA)收缩的STEMI患者其左降动脉(LAD)用经皮冠状动脉介入治疗(PCI)的，其结果更糟糕。
  
原始出处：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-08-08 jambiya

    #危险信号#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-08-11 canlab

    #NET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2016-02-05 12498c32m68暂无昵称

    #STEMI患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-05-07 zhaojie88

    #ART#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-05-07 12498bb3m92(暂无昵称)

    #STEM#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-05-07 slcumt

    #HEART#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2060482, encodeId=caea206048242, content=<a href='/topic/show?id=6b5e36e72d8' target=_blank style='color:#2F92EE;'>#危险信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36772, encryptionId=6b5e36e72d8, topicName=危险信号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sat Aug 08 19:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733741, encodeId=8d151e3374197, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Aug 11 20:42:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936692, encodeId=ad3f1936692b4, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Feb 05 05:42:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355982, encodeId=4ec41355982ec, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481864, encodeId=fb0214818647c, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562304, encodeId=2364156230433, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu May 07 04:42:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22741, encodeId=a73022e41aa, content=新的研究方向！, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:23:00 CST 2015, time=2015-05-06, status=1, ipAttribution=)]
    2015-05-06 qingfengqishi5

    新的研究方向！

    0

相关资讯

JAMA：二甲双胍或不改善STEMI患者左室射血分数

2014年美国心脏病学会年会（ACC2014）公布的GIPS-III研究表明，在不伴随糖尿病、直接行经皮冠状动脉介入治疗(PCI)的ST段抬高性心肌梗死(STEMI)患者中，与应用安慰剂相比，应用二甲双胍不改善患者4个月后的左心室射血分数(LVEF)。研究论文3月30日在线发表于《美国医学会杂志》。 GIPS-III研究(对行PCI治疗的STEMI患者辅助降糖干预治疗)是一项双盲、安慰剂对照研究

ACC 2014：早期静脉用β阻滞剂或可减少STEMI患者梗死面积

2014年美国心脏病学会年会（ACC 2014）公布的METOCARD-CNIC研究表明，在直接行经皮冠状动脉介入(PCI)治疗的ST段抬高性心肌梗死(STEMI)患者中，早期静脉应用β阻滞剂与5-7天时梗死面积减少有相关性，这进而改善了患者6个月时的左心室射血分数。虽然该研究的临床终点不够有力，但在美托洛尔组中，有不良心血管事件减少的有利趋势。 该随机平行分层研究纳入270例患者，平均年龄为5

EuroPCR 2014：吗啡或延缓新型口服抗血小板药起效时间

一项新研究表明，在因ST段抬高性心肌梗死(STEMI)而接受直接经皮冠状动脉介入治疗(PCI)的患者中，吗啡应用可能延缓新型口服抗血小板药的起效时间，进而可能增加患者风险。Guido Parodi博士在2014年欧洲血运重建大会(EuroPCR 2014)上报告了上述研究。他强调，虽然该研究只观察了血小板反应性而未观察硬临床事件，但医生也应注意新型P2Y12抑制剂和吗啡的潜在相互作用。 研究者既

Lancet：直接PCI怪象：“门-球时间”逐年缩短，人群层面死亡风险不降反升

最新的回顾性研究显示，平均“门-球时间”（就诊至球囊扩张时间，D2B）的减少并没有带来患病人口层面上死亡率的降低，来自于密歇根、哈佛、耶鲁等医学院校的研究者们的研究者们对这一看似矛盾的现象进行了相关调查，他们通过同时对病人群体在人口层面和个体层面上进行组分分析来进行寻找其原因。研究者提出假说：接受直接PCI（pPCI）治疗的人群组成的变化导致了群体死亡率逐年增加这一奇怪倾向；然而不可否让，更短

STEMI合并多支病变：完全血运重建吗?

STEMI合并多支病变：是否行完全血运重建? 哈尔滨医科大学附属第一医院李为民教授、薛竟宜医师介绍，研究报告约41%~67%急性STEMI患者合并有多支血管病变，其远期心血管事件较单支血管病变患者明显升高。 目前各指南均明确提出，对不合并血流动力学障碍的STEMI患者，仅干预梗死相关动脉。2014年欧洲《心肌血运重建指南》仍推荐，在不合并心源性休克和持续心肌缺血时，仅处理罪犯血管(Ⅱ

NEJM：血栓切除术，做还是不做？( TOTAL试验)

背景：在主要经皮冠状动脉脉介入治疗即PCI治疗中，手动血栓切除术可以减少远端血栓的存在从而改善微循环灌注，小规模试验表明血栓切除术可以改善替代治疗和临床效果，但是稍复杂的试验则会出现有争议的临床结果。研究方式：我们随机分配10732位ST段抬高型心肌梗死即STEMI的患者接受两种治疗：常规PCI治疗（对照组）和进行手动血栓切除术后进行PCI术（即实验组）。我们关注的主要指标是：心血管疾病原因导致的